Symmetry Partners, LLC Amgen Inc Transaction History

Symmetry Partners, LLC

$422 Million
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 11, 2024	SELL	$262.75 - $319.31 $144,249 - $175,301	-549 Reduced 13.78%	3,436 $1.07 Million
Q1 2023 Apr 03, 2023	SELL	$225.79 - $275.2 $1.83 Million - $2.22 Million	-8,084 Reduced 66.98%	3,985 $963,000
Q4 2022 Jan 06, 2023	BUY	$229.03 - $291.01 $1.82 Million - $2.32 Million	7,959 Added 193.65%	12,069 $3.17 Million
Q4 2021 Jan 11, 2022	BUY	$198.88 - $227.6 $316,616 - $362,339	1,592 Added 63.22%	4,110 $925,000
Q3 2021 Oct 18, 2021	SELL	$212.27 - $248.7 $1.02 Million - $1.2 Million	-4,826 Reduced 65.71%	2,518 $533,000
Q1 2021 May 03, 2021	SELL	$221.91 - $258.6 $79,443 - $92,578	-358 Reduced 4.65%	7,344 $1.83 Million
Q4 2020 Feb 18, 2021	SELL	$216.38 - $257.67 $966,785 - $1.15 Million	-4,468 Reduced 36.71%	7,702 $1.77 Million
Q3 2020 Nov 03, 2020	BUY	$234.65 - $260.95 $1.64 Million - $1.82 Million	6,991 Added 134.99%	12,170 $3.09 Million
Q2 2020 Jul 20, 2020	BUY	$197.81 - $242.74 $781,151 - $958,580	3,949 Added 321.06%	5,179 $1.22 Million
Q1 2020 May 15, 2020	BUY	$182.24 - $241.7 $224,155 - $297,291	1,230 New	1,230 $249,000
Q4 2019 Feb 12, 2020	SELL	$189.21 - $243.2 $282,679 - $363,340	-1,494 Closed	0 $0
Q3 2019 Nov 04, 2019	SELL	$174.11 - $208.62 $59,023 - $70,722	-339 Reduced 18.49%	1,494 $289,000
Q2 2019 Aug 07, 2019	SELL	$166.7 - $195.41 $874,174 - $1.02 Million	-5,244 Reduced 74.1%	1,833 $338,000
Q1 2019 May 13, 2019	BUY	$180.87 - $203.88 $363,186 - $409,391	2,008 Added 39.61%	7,077 $1.34 Million
Q4 2018 May 22, 2019	BUY	$178.4 - $208.25 $904,309 - $1.06 Million	5,069 New	5,069 $987,000

Others Institutions Holding AMGN

# of Institutions

3,084

Shares Held

417M

Call Options Held

7.18M

Put Options Held

6.28M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $171B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Symmetry Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Symmetry Partners, LLC with notifications on news.

Account